ADHD Drug Cardiac Events, COX-2s Are Topics For Drug Safety Committee Meeting

Studies to determine risk of cardiovascular adverse outcomes with attention deficit/hyperactivity disorder drugs will be discussed at Feb. 9-10 meeting. Risk management programs for isotretinoin products also on the agenda.